Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00151736 · Cephalon · PHASE2 · terminated · last registry update 2012-06-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Cephalon |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RXRA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-04-16Also stopped (terminated): Fox Chase Cancer Center, Bexarotene 1% gel (NCT00322296)
- 2013-01-16Also stopped (withdrawn): University of Pittsburgh, Acitretin (NCT01299220)
- 2012-07-26Also stopped (terminated): Emergent Product Development Seattle LLC, HuMax-CD4 (zanolimumab) (NCT00127881)
- 2012-04-17Phase 3 first posted: Millennium Pharmaceuticals, Inc., Brentuximab Vedotin + Methotrexate (NCT01578499)
- 2012-04-09Results posted on the registry: Pfizer, Etanercept + Etanercept + Acitretin (NCT00936065)
- 2012-03-06Phase 3 first posted: Innovaderm Research Inc., Acitretin (NCT01545284)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision